Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors

Summary

This randomized phase II trial studies how well pazopanib hydrochloride works in treating patients with carcinoid tumors that are growing, spreading, or getting worse. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Conditions

• Foregut Neuroendocrine Tumor
• Hindgut Neuroendocrine Tumor
• Metastatic Digestive System Neuroendocrine Tumor G1
• Metastatic Neuroendocrine Tumor
• Midgut Neuroendocrine Tumor G1
• Neuroendocrine Tumor G2
• Recurrent Digestive System Neuroendocrine Tumor G1
• Regional Digestive System Neuroendocrine Tumor G1

Interventions

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Computed Tomography

Undergo CT

PROCEDURE

Echocardiography Test

Undergo ECHO

OTHER

Laboratory Biomarker Analysis

Correlative studies

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

PROCEDURE

Multigated Acquisition Scan

Undergo MUGA

DRUG

Pazopanib Hydrochloride

Given PO

OTHER

Placebo Administration

Given PO

OTHER

Quality-of-Life Assessment

Ancillary studies

PROCEDURE

X-Ray Imaging

Undergo chest x-ray

Sponsors & Collaborators

• National Cancer Institute (NCI)

  lead NIH

Principal Investigators

• Emily K Bergsland · Alliance for Clinical Trials in Oncology

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Model

CROSSOVER

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2013-09-20

Primary Completion

2019-03-05

Completion

2026-09-10

Countries

• United States
• Canada

Study Locations